Evofem Biosciences, Inc. (EVFM) stock
EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026Market cap $865.23KP/E –Yield –
Evofem Biosciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Evofem Biosciences's ebitda for the twelve months ending Jun 30, 2023 was -$40.77M. For fiscal 2023 it was -$17.37M. The highest annual figure on record is -$9.57M in fiscal 2014.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$17.37M | – |
| FY2022 | Dec 31, 2022 | -$83.11M | – |
| FY2021 | Dec 31, 2021 | -$165.78M | – |
| FY2020 | Dec 31, 2020 | -$103.32M | – |
| FY2019 | Dec 31, 2019 | -$52.48M | – |
| FY2018 | Dec 31, 2018 | -$77.38M | – |
| FY2017 | Dec 31, 2017 | -$35.44M | – |
| FY2016 | Dec 31, 2016 | -$11.97M | – |
| FY2015 | Dec 31, 2015 | -$41.99M | – |
| FY2014 | Dec 31, 2014 | -$9.57M | – |
| FY2013 | Dec 31, 2013 | -$14.35M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | -$7.16M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.33M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.80M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.47M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.17M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.66M | – |
| Q4 FY2021 | Dec 31, 2021 | -$37.13M | – |
| Q3 FY2021 | Sep 30, 2021 | -$43.10M | – |
| Q2 FY2021 | Jun 30, 2021 | -$40.87M | – |
| Q1 FY2021 | Mar 31, 2021 | -$44.68M | – |
| Q4 FY2020 | Dec 31, 2020 | -$35.73M | – |
| Q3 FY2020 | Sep 30, 2020 | -$26.10M | – |
| Q2 FY2020 | Jun 30, 2020 | -$22.32M | – |
| Q1 FY2020 | Mar 31, 2020 | -$19.18M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.81M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.23M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.88M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.57M | – |
| Q4 FY2018 | Dec 31, 2018 | -$14.92M | – |
| Q3 FY2018 | Sep 30, 2018 | -$18.37M | – |
| Q2 FY2018 | Jun 30, 2018 | -$23.18M | – |
| Q1 FY2018 | Mar 31, 2018 | -$20.92M | – |
| Q4 FY2017 | Dec 31, 2017 | -$15.28M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.00M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.29M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.87M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.97M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.85M | – |
| Q2 FY2016 | Jun 30, 2016 | -$2.50M | – |
See a number that looks wrong?